FTC targets Martin Shkreli over pharma stock trading and market commentary

The FTC and seven state attorneys general are requesting a federal judge to find Martin Shkreli in contempt of court. According to the FTC, Shkreli has flagrantly and repeatedly violated a lifetime pharma ban. The regulatory action specifically targets his activities regarding pharma stock trading and his public market commentary. These legal efforts aim to address the repeated breaches of the previous judicial restrictions imposed on Shkreli concerning the pharmaceutical industry and related financial markets.